Fosphenytoin
| Evidence Level: L5 | Predicted Indications: 7 |
Table of Contents
Fosphenytoin: Conjunctivitis
One-Sentence Summary
Fosphenytoin is an intravenous prodrug of phenytoin, originally used to treat epilepsy and status epilepticus. The TxGNN model predicts it may be effective for conjunctivitis, but this is a TxGNN model (deep learning) prediction only, with 0 clinical trials and 0 publications supporting it. Among the other predicted indications, only manic bipolar affective disorder has any published evidence (1 small publication).
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in the local data |
| Predicted New Indication | Conjunctivitis |
| TxGNN Prediction Score | 0.9936 |
| Evidence Level | L5 |
| Canada Market Status | Marketed (marketed DINs: 1 of 1) |
| Number of DINs | 1 (marketed: 1) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not available in the data compiled for this report. Fosphenytoin is a prodrug of phenytoin, a voltage-gated sodium channel blocker, and its efficacy in seizure control is established.
For conjunctivitis, there is no clear mechanistic link. Conjunctivitis is typically infectious or allergic/inflammatory, and sodium channel blockade has no established role in it. The high score (0.9936) comes from the TxGNN model (deep learning) and may reflect similarities the model learned between related diseases, not biological evidence. Phenytoin is also associated with hypersensitivity reactions, which could plausibly worsen ocular inflammatory conditions.
Other predicted indications (for reference):
| Predicted Indication | Score | Evidence Level | Assessment |
|---|---|---|---|
| Nephrogenic syndrome of inappropriate antidiuresis | 0.9928 | L5 | No action on the V2 receptor pathway; phenytoin can cause SIADH-like hyponatremia, which argues against benefit |
| Tourette syndrome | 0.9922 | L5 | No established rationale; IV dosing and cardiac monitoring are impractical for a chronic tic disorder |
| Manic bipolar affective disorder | 0.9918 | L5 | Plausible class-level rationale, since other anticonvulsants are mood stabilizers; one small publication; research question |
| Myositis fibrosa | 0.9902 | L5 | No identified mechanistic link |
| Idiopathic granulomatous myositis | 0.9902 | L5 | No immunomodulatory role; same score as myositis fibrosa suggests a similarity the TxGNN model (deep learning) learned between related diseases, not biological evidence |
| Fibromyalgia | 0.9902 | L5 | Loose class-level rationale only; IV dosing is a poor fit for chronic pain |
Clinical Trial Evidence
Currently no related clinical trials registered for conjunctivitis (nor for any of the other predicted indications).
Literature Evidence
Currently no related literature available for conjunctivitis.
For reference, the only publication retrieved across all predicted indications relates to manic bipolar affective disorder:
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 12716241 | 2003 | Small pilot study / case report (to be verified from full text) | The Journal of Clinical Psychiatry | Tested the hypothesis that high-dose intravenous fosphenytoin might be acutely antimanic, using a prodrug with fewer cardiac and local vein side effects than phenytoin |
Canada Market Information
| DIN | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| 02230988 | CEREBYX | Not listed | Not listed |
Safety Considerations
Knowledge-graph contraindication signals (from drug-disease contraindication edges, not label text):
- Cardiac and conduction: long QT syndrome (including familial), torsades de pointes, sudden cardiac arrest, heart conduction disease, atrioventricular block, Adams-Stokes syndrome, hypotensive disorder
- Haematological: thrombocytopenia, leukopenia, pancytopenia, agranulocytosis, neutropenia (including congenital and cyclic forms), lymphatic system disease
- Organ function: kidney disease, liver disease, gallbladder disease, pyoureter
- Other: systemic lupus erythematosus (including paediatric), substance abuse/dependence, hyperphosphatemia
Drug Interactions: The interaction screen returned 100 interactions. Examples:
- Major: cimetidine, eliglustat
- Moderate: acarbose, famotidine, ranitidine, doxycycline, hydrocortisone, betamethasone, clarithromycin, aprepitant, canagliflozin, dulaglutide, and others
- Minor: acetylsalicylic acid
Package insert warnings and contraindications from Health Canada were not available. Please refer to the package insert for full safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The conjunctivitis prediction rests on the model score alone. There are no trials or publications, no plausible mechanism, and a possible hypersensitivity concern. The same applies to most of the other predicted indications. Manic bipolar affective disorder is the only one with a plausible rationale and a (small, preliminary) publication, and it could be considered a research question.
To proceed, the following is needed:
- Health Canada package insert warnings and contraindications (a blocking gap for safety screening)
- Mechanism of action data
- Full-text review of PMID 12716241 to confirm study design and results if the mania direction is pursued
- Route compatibility assessment, since fosphenytoin is given intravenously and chronic or ocular conditions may need other routes
- Any preclinical or clinical evidence supporting a role in conjunctivitis
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.